Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes the challenges ahead for the European biosimilars market.
Transcript:
If I look at the market unfolding, let's say, I think one of the very important notions that needs to be reconciled is the short-term policy regarding budget management and the longer-term goal of healthcare equity and a greater quality of care because you can't forget that end goal and compromise it; you need to make sure you have thoughtful policies in place today so that you're not compromising meeting the big end goal.
I think this is essential and it has to do with a general education that competition in the pharmaceutical market is a dynamic and cyclic system, and for that, the time element is really important. It has to be seen in a bigger time frame than just the cycle of a call for tender or a purchasing bid, or this type of element.
For us, the challenge this year will be to make sure everybody in the healthcare community, from the makers to the end users, do have that time element to it. Yes there is “what's in it for me?” at every bit, but I think the time element will condition how deliverables are are actually happening or not, so this is really important.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.